These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 23646191)
1. Effectiveness of MF59™ adjuvanted influenza A(H1N1)pdm09 vaccine in risk groups in the Netherlands. Wijnans L; Dieleman J; Voordouw B; Sturkenboom M PLoS One; 2013; 8(4):e63156. PubMed ID: 23646191 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness of A(H1N1)pdm09 influenza vaccine in adults recommended for annual influenza vaccination. Gefenaite G; Tacken M; Bos J; Stirbu-Wagner I; Korevaar JC; Stolk RP; Wolters B; Bijl M; Postma MJ; Wilschut J; Nichol KL; Hak E PLoS One; 2013; 8(6):e66125. PubMed ID: 23840413 [TBL] [Abstract][Full Text] [Related]
3. Usefulness of health registries when estimating vaccine effectiveness during the influenza A(H1N1)pdm09 pandemic in Norway. Guzmán Herrador BR; Aavitsland P; Feiring B; Riise Bergsaker MA; Borgen K BMC Infect Dis; 2012 Mar; 12():63. PubMed ID: 22429643 [TBL] [Abstract][Full Text] [Related]
4. 2015/16 I-MOVE/I-MOVE+ multicentre case-control study in Europe: Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage-mismatched influenza B among children. Kissling E; Valenciano M; Pozo F; Vilcu AM; Reuss A; Rizzo C; Larrauri A; Horváth JK; Brytting M; Domegan L; Korczyńska M; Meijer A; Machado A; Ivanciuc A; Višekruna Vučina V; van der Werf S; Schweiger B; Bella A; Gherasim A; Ferenczi A; Zakikhany K; O Donnell J; Paradowska-Stankiewicz I; Dijkstra F; Guiomar R; Lazar M; Kurečić Filipović S; Johansen K; Moren A; Influenza Other Respir Viruses; 2018 Jul; 12(4):423-437. PubMed ID: 29125681 [TBL] [Abstract][Full Text] [Related]
5. Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. Andrews N; Waight P; Yung CF; Miller E J Infect Dis; 2011 Jan; 203(1):32-9. PubMed ID: 21148494 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness of a MF-59™-adjuvanted pandemic influenza vaccine to prevent 2009 A/H1N1 influenza-related hospitalisation; a matched case-control study. Steens A; Wijnans EG; Dieleman JP; Sturkenboom MC; van der Sande MA; van der Hoek W BMC Infect Dis; 2011 Jul; 11():196. PubMed ID: 21767348 [TBL] [Abstract][Full Text] [Related]
7. Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15. Valenciano M; Kissling E; Reuss A; Rizzo C; Gherasim A; Horváth JK; Domegan L; Pitigoi D; Machado A; Paradowska-Stankiewicz IA; Bella A; Larrauri A; Ferenczi A; ; Lazar M; Pechirra P; Korczyńska MR; Pozo F; Moren A; Euro Surveill; 2016; 21(7):pii=30139. PubMed ID: 26924024 [TBL] [Abstract][Full Text] [Related]
8. Did the H1N1 Vaccine Reduce the Risk of Admission with Influenza and Pneumonia during the Pandemic? Mahmud SM; Bozat-Emre S; Hammond G; Elliott L; Van Caeseele P PLoS One; 2015; 10(11):e0142754. PubMed ID: 26600435 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness of the trivalent MF59 adjuvated influenza vaccine in preventing hospitalization due to influenza B and A(H1N1)pdm09 viruses in the elderly in Italy, 2017 - 2018 season. Bella A; Gesualdo F; Orsi A; Arcuri C; Chironna M; Loconsole D; Napoli C; Orsi GB; Manini I; Montomoli E; Alfonsi V; Castrucci MR; Rizzo C Expert Rev Vaccines; 2019 Jun; 18(6):671-679. PubMed ID: 31159616 [No Abstract] [Full Text] [Related]
10. Influence of Birth Cohort on Effectiveness of 2015-2016 Influenza Vaccine Against Medically Attended Illness Due to 2009 Pandemic Influenza A(H1N1) Virus in the United States. Flannery B; Smith C; Garten RJ; Levine MZ; Chung JR; Jackson ML; Jackson LA; Monto AS; Martin ET; Belongia EA; McLean HQ; Gaglani M; Murthy K; Zimmerman R; Nowalk MP; Griffin MR; Keipp Talbot H; Treanor JJ; Wentworth DE; Fry AM J Infect Dis; 2018 Jun; 218(2):189-196. PubMed ID: 29361005 [TBL] [Abstract][Full Text] [Related]
11. Long term effectiveness of adjuvanted influenza A(H1N1)pdm09 vaccine in children. Örtqvist Å; Bennet R; Hamrin J; Rinder MR; Lindblad H; Öhd JN; Eriksson M Vaccine; 2015 May; 33(22):2558-61. PubMed ID: 25869891 [TBL] [Abstract][Full Text] [Related]
12. Influenza vaccine effectiveness in preventing laboratory-confirmed influenza in outpatient settings: A test-negative case-control study in Beijing, China, 2016/17 season. Wu S; Pan Y; Zhang X; Zhang L; Duan W; Ma C; Zhang Y; Zhang M; Sun Y; Yang P; Wang Q; Ma J Vaccine; 2018 Sep; 36(38):5774-5780. PubMed ID: 30087046 [TBL] [Abstract][Full Text] [Related]
13. The European I-MOVE Multicentre 2013-2014 Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2). Valenciano M; Kissling E; Reuss A; Jiménez-Jorge S; Horváth JK; Donnell JM; Pitigoi D; Machado A; Pozo F; Vaccine; 2015 Jun; 33(24):2813-22. PubMed ID: 25936723 [TBL] [Abstract][Full Text] [Related]
14. Beyond Antigenic Match: Possible Agent-Host and Immuno-epidemiological Influences on Influenza Vaccine Effectiveness During the 2015-2016 Season in Canada. Skowronski DM; Chambers C; Sabaiduc S; De Serres G; Winter AL; Dickinson JA; Gubbay JB; Drews SJ; Martineau C; Charest H; Krajden M; Bastien N; Li Y J Infect Dis; 2017 Dec; 216(12):1487-1500. PubMed ID: 29029166 [TBL] [Abstract][Full Text] [Related]
15. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial. Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857 [TBL] [Abstract][Full Text] [Related]
16. Moderate influenza vaccine effectiveness against A(H1N1)pdm09 virus, and low effectiveness against A(H3N2) subtype, 2018/19 season in Italy. Bellino S; Bella A; Puzelli S; Di Martino A; Facchini M; Punzo O; Pezzotti P; Castrucci MR; The InfluNet Study Group Expert Rev Vaccines; 2019 Nov; 18(11):1201-1209. PubMed ID: 31674847 [No Abstract] [Full Text] [Related]
17. An indirect comparison meta-analysis of AS03 and MF59 adjuvants in pandemic influenza A(H1N1)pdm09 vaccines. Hauser MI; Muscatello DJ; Soh ACY; Dwyer DE; Turner RM Vaccine; 2019 Jul; 37(31):4246-4255. PubMed ID: 31253447 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. Skowronski DM; Janjua NZ; De Serres G; Hottes TS; Dickinson JA; Crowcroft N; Kwindt TL; Tang P; Charest H; Fonseca K; Gubbay JB; Bastien N; Li Y; Petric M BMJ; 2011 Feb; 342():c7297. PubMed ID: 21292718 [TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age. Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803 [TBL] [Abstract][Full Text] [Related]